Two cases of agranulocytosis on addition of a butyrophenone to a long-standing course of phenothiazine treatment.
Two cases of agranulocytosis occurring after addition of a butyrophenone to a course of phenothiazine treatment are reported and possible mechanisms for this interaction are discussed.
Young
A
A
Royal Edinburgh Hospital.
Kehoe
R
R
D000380:Agranulocytosis / Q000139:chemically induced*; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002746:Chlorpromazine / Q000009:adverse effects; D002997:Clomipramine / Q000009:adverse effects; D003866:Depressive Disorder / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004329:Droperidol / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D005475:Flupenthixol / Q000009:adverse effects / Q000031:analogs & derivatives; D005476:Fluphenazine / Q000009:adverse effects / Q000031:analogs & derivatives; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D010259:Paranoid Disorders / Q000188:drug therapy*; D011618:Psychotic Disorders / Q000188:drug therapy*
D014150:Antipsychotic Agents; C007761:flupenthixol decanoate; D005475:Flupenthixol; C011825:fluphenazine depot; D002997:Clomipramine; D004329:Droperidol; D005476:Fluphenazine; D002746:Chlorpromazine